PARIS--(BUSINESS WIRE)-- ExonHit Therapeutics (Paris:ALEHT) today announced successful completion of the first phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.
